CD8A and neoplasm: PM-encapsulation of the toll-like receptor agonist R848 prolongs its retention within colorectal tumors, lowering the required dosage while potently activating antigen-presenting cells and driving CD8+ T-cell infiltration to induce tumor regression [122].